13F filer · CIK 1622627
Rosalind Advisors, Inc.
TORONTO, A6 · filing since Q4 2023 · last filing Aug 14, 2026
Reported value
$269.2M
$-122.9M vs prior
Positions
35
New / sold out
9 / 12
Added / reduced
7 / 11
Turnover
7.6%
buys $25.2M · sells $185.6M
Top-10 weight
74.0%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Added | VERASTEM INC | +1,848,034 | +86.4% | +$7.1M |
| Added | FENNEC PHARMACEUTICALS INC | +279,800 | +9.6% | +$3.0M |
| Added | CYBIN INC | +425,000 | +27.7% | +$2.8M |
| New | ABIVAX SA | +20,869 | – | +$2.8M |
| New | SELLAS LIFE SCIENCES GROUP INCPUT | +568,700 | – | +$2.3M |
| Added | TALPHERA INC | +1,815,585 | +54.1% | +$1.9M |
| Added | REGENTIS BIOMATERIALS LTD | +450,175 | +179.0% | +$1.6M |
| Added | NEURAXIS INC | +221,917 | +77.6% | +$1.3M |
| New | SPRUCE BIOSCIENCES INC | +20,000 | – | +$1.1M |
| New | PEPGEN INC | +350,000 | – | +$630.0K |
6 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | INVESCO QQQ TRPUT | -250,000 | -100.0% | $-144.3M |
| Sold out | CG ONCOLOGY INC | -100,000 | -100.0% | $-6.8M |
| Reduced | VAXCYTE INC | -90,000 | -31.0% | $-5.2M |
| Sold out | VIRIDIAN THERAPEUTICS INC | -250,401 | -100.0% | $-4.9M |
| Reduced | CELLDEX THERAPEUTICS INC | -130,000 | -39.4% | $-4.8M |
| Sold out | REPLIMUNE GROUP INCCALL | -1,275,600 | -100.0% | $-2.7M |
| Reduced | XERIS BIOPHARMA HOLDINGS INC | -322,719 | -10.0% | $-2.6M |
| Sold out | DEFINIUM THERAPEUTICS INC | -125,000 | -100.0% | $-2.4M |
| Reduced | BIOCRYST PHARMACEUTICALS INC | -201,553 | -21.8% | $-2.0M |
| Sold out | LIPOCINE INC | -221,616 | -100.0% | $-1.8M |
13 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | DELCATH SYSTEMS, INC.COM NEW | 3,300,389 | $41.6M | 15.44% |
| 2 | FENNEC PHARMACEUTICALS INCCOM | 3,188,001 | $34.3M | 12.73% |
| 3 | XERIS BIOPHARMA HOLDINGS INCCOM | 2,908,981 | $23.0M | 8.56% |
| 4 | SAVARA INCCOM | 3,178,121 | $19.6M | 7.27% |
| 5 | VERASTEM INCCOM NEW | 3,986,509 | $15.2M | 5.66% |
| 6 | X4 PHARMACEUTICALS INCCOM NEW | 3,214,766 | $15.0M | 5.58% |
| 7 | EYEPOINT PHARMACEUTICALS INCCOM NEW | 988,230 | $14.1M | 5.25% |
| 8 | CYBIN INCCOM NEW | 1,956,814 | $12.9M | 4.80% |
| 9 | VOR BIOPHARMA INCCOM NEW | 648,600 | $11.9M | 4.44% |
| 10 | VAXCYTE INCCOM | 200,000 | $11.6M | 4.32% |
25 more rows. Subscribe for $29/month to see every row, download the data and use the API.